AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9423948 — intervention group
Group type: COMPARATOR
Intervention: Group II (n = 26)
Number of subjects: 52
Study 7534945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 12
Study 7534945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 and Enoxaparin
Number of subjects: 12
Study 7534945 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 12
Study 7534945 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Enoxaparin and Dextran
Number of subjects: 12
Study 3297566 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual dilatation of the anus
Number of subjects: 111
Study 3297566 — intervention group
Group type: COMPARATOR
Intervention: Lateral subcutaneous sphincterotomy
Number of subjects: 111
Study 30169321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 106
Study 30169321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 26839889 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 0
Study 26839889 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI4 (four injections daily, glargine based)
Number of subjects: 0
Study 26839889 — intervention group
Group type: COMPARATOR
Intervention: MDI3 (three injections daily, aspart 30-based)
Number of subjects: 0
Study 24730050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (5mg q4h)
Number of subjects: 506
Study 24730050 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 506
Study 22687231 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher numbers of drugs prescribed during follow-up
Number of subjects: 597
Study 22687231 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased energy intake
Number of subjects: 597
Study 22687231 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 597
Study 22687231 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics (older individuals, males, larger waist circumference)
Number of subjects: 597
Study 22687231 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelled CVD risk after 14 months
Number of subjects: 597
Study 20687970 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifibre mixture with prebiotic components
Number of subjects: 27
Study 20687970 — intervention group
Group type: COMPARATOR
Intervention: Fibre-free period
Number of subjects: 27
Study 19248655 — intervention group
Group type: EXPERIMENTAL
Intervention: MA 60 mg/kg/day/ IM and oral placebo for three weeks
Number of subjects: 150
Study 19248655 — intervention group
Group type: EXPERIMENTAL
Intervention: MA 30 mg/kg/day/IM and oral omeprazole 40 mg/day for three weeks
Number of subjects: 150
Study 19248655 — intervention group
Group type: COMPARATOR
Intervention: MA 30 mg/kg/day/IM and oral placebo for three weeks
Number of subjects: 150
Study 15993827 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap selection based on vehicle distance
Number of subjects: 3
Study 15993827 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap selection based on time-of-arrival
Number of subjects: 3
Study 15993827 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap selection by old-old adults
Number of subjects: 3
Study 12970225 — intervention group
Group type: EXPERIMENTAL
Intervention: RV to PA conduit (RV/PA)
Number of subjects: 56
Study 12970225 — intervention group
Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt (BTS)
Number of subjects: 56
Study 10629357 — intervention group
Group type: EXPERIMENTAL
Intervention: eptastigmine 10 mg t.i.d. and 12 mg t.i.d. for 25 weeks
Number of subjects: 349
Study 10629357 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 349
Study 10629357 — intervention group
Group type: EXPERIMENTAL
Intervention: eptastigmine
Number of subjects: 349
Study 8795261 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 instructional visits
Number of subjects: 0
Study 8795261 — intervention group
Group type: COMPARATOR
Intervention: 3 instructional visits
Number of subjects: 0
Study 8795261 — intervention group
Group type: COMPARATOR
Intervention: 0 instructional visits
Number of subjects: 0
Study 1621223 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG + A
Number of subjects: 80
Study 1621223 — intervention group
Group type: COMPARATOR
Intervention: A
Number of subjects: 80
Study 6827407 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (53 children)
Number of subjects: 181
Study 6827407 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group (128 children)
Number of subjects: 181
Study 6827407 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treated and untreated children
Number of subjects: 181
Study 6827407 — intervention group
Group type: COMPARATOR
Intervention: Untreated children
Number of subjects: 181
Study 6827407 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with increased sensitivity
Number of subjects: 181
Study 31123008 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 70-90 mg/kg/day for 3 or 7 days
Number of subjects: 800
Study 31123008 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 35-50 mg/kg/day for 3 or 7 days
Number of subjects: 800
Study 31123008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 31123008 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (both dosages)
Number of subjects: 800
Study 30192166 — intervention group
Group type: EXPERIMENTAL
Intervention: meropenem/colistin
Number of subjects: 47
Study 30192166 — intervention group
Group type: COMPARATOR
Intervention: meropenem/ampicillin-sulbactam
Number of subjects: 47
Study 27427128 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based procedure (Group A)
Number of subjects: 210
Study 27427128 — intervention group
Group type: COMPARATOR
Intervention: Random shunt placement (Group B)
Number of subjects: 210
Study 25175805 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5042
Study 25175805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5042
Study 22002249 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate treatment (simple, low-cost environmental modifications)
Number of subjects: 0
Study 22002249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense treatment (added elements to engage management)
Number of subjects: 0
Study 22002249 — intervention group
Group type: COMPARATOR
Intervention: Both treatment conditions (moderate vs. intense)
Number of subjects: 0
Study 19459810 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 20
Study 17325603 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)
Number of subjects: 422
Study 17325603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 422
Study 17325603 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor + Nonnucleoside reverse transcriptase inhibitor (PI + NNRTI)
Number of subjects: 422
Study 15167542 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality
Number of subjects: 0
Study 15167542 — intervention group
Group type: COMPARATOR
Intervention: No virtual reality
Number of subjects: 0
Study 11449531 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 800 micrograms/daily
Number of subjects: 16
Study 11449531 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 840 micrograms/daily
Number of subjects: 16
Study 9684692 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) administered before meals
Number of subjects: 12
Study 9684692 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3) administered during meals
Number of subjects: 12
Study 7511495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (6% wt/vol, average molecular weight 200 kilodaltons)
Number of subjects: 10
Study 7511495 — intervention group
Group type: COMPARATOR
Intervention: Human albumin (5% albumin solution)
Number of subjects: 10
Study 2894751 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) infusion (20 mU/kg/h)
Number of subjects: 8
Study 2894751 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study 29386053 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine removal of the syndesmotic screw
Number of subjects: 194
Study 29386053 — intervention group
Group type: COMPARATOR
Intervention: Removal on demand of the syndesmotic screw
Number of subjects: 194
Study 27058712 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sedation with midazolam
Number of subjects: 80
Study 27058712 — intervention group
Group type: COMPARATOR
Intervention: Moderate sedation with midazolam
Number of subjects: 80
Study 23889803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (4 mg)
Number of subjects: 24
Study 23889803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg)
Number of subjects: 24
Study 23889803 — intervention group
Group type: COMPARATOR
Intervention: Control group (cataract surgery patients)
Number of subjects: 24
Study 22356350 — intervention group
Group type: EXPERIMENTAL
Intervention: MP29-02
Number of subjects: 6
Study 22356350 — intervention group
Group type: COMPARATOR
Intervention: MP29-02-FP-mono
Number of subjects: 6
Study 22356350 — intervention group
Group type: COMPARATOR
Intervention: FP-BI
Number of subjects: 6
Study 20052461 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib (n = 8)
Number of subjects: 12
Study 20052461 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 12
Study 18323726 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian massage (20 min, 3 times per week for 4 weeks)
Number of subjects: 34
Study 17117227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapericardial triamcinolone hexacetonide 200 mg
Number of subjects: 57
Study 17117227 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone plus intrapericardial placebo
Number of subjects: 57
Study 17117227 — intervention group
Group type: COMPARATOR
Intervention: Intrapericardial 0.9% saline (placebo)
Number of subjects: 57
Study 14664167 — intervention group
Group type: EXPERIMENTAL
Intervention: Arifon retard monotherapy
Number of subjects: 95
Study 14664167 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of arifon retard and climonorm
Number of subjects: 95
Study 14664167 — intervention group
Group type: EXPERIMENTAL
Intervention: Arifon retard in combination with climonorm
Number of subjects: 95
Study 10655249 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes in women
Number of subjects: 5653
Study 10655249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin levels in women
Number of subjects: 5653
Study 10655249 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide levels in women
Number of subjects: 5653
Study 10655249 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes in men
Number of subjects: 5653
Study 10655249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin and C-peptide in men
Number of subjects: 5653
Study 8987189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline-fluphenazine (NF)
Number of subjects: 16
Study 8987189 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CMZ)
Number of subjects: 16
Study 1338389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg once daily for 24 weeks
Number of subjects: 48
Study 1338389 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 24 weeks
Number of subjects: 48
Study 6711261 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 0.1 mg/kg
Number of subjects: 40
Study 6711261 — intervention group
Group type: COMPARATOR
Intervention: sodium chloride
Number of subjects: 40
Study 30257036 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) alone
Number of subjects: 9
Study 30257036 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) and deproteinized bovine bone mineral (DBBM)
Number of subjects: 9
Study 30235759 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary hospitals
Number of subjects: 896
Study 30235759 — intervention group
Group type: COMPARATOR
Intervention: Tertiary hospitals
Number of subjects: 896
Study 30235759 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 896
Study 27322462 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg finasteride daily for 4-6 weeks
Number of subjects: 183
Study 27322462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 24224738 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week aerobic training programme, 3 sessions per week, treadmill exercise (30-40 min) at 55-65% of peak heart rate
Number of subjects: 20
Study 24224738 — intervention group
Group type: COMPARATOR
Intervention: No training programme
Number of subjects: 20
Study 22488225 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive hamstring stretching (3 times for 30 seconds)
Number of subjects: 34
Study 22488225 — intervention group
Group type: COMPARATOR
Intervention: No stretching or movement (Control)
Number of subjects: 34
Study 20416389 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled magnesium sulfate (333 mg in 3 ml solution)
Number of subjects: 60
Study 20416389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 ml isotonic saline solution with albuterol and ipratropium)
Number of subjects: 60
Study 17700289 — intervention group
Group type: EXPERIMENTAL
Intervention: GDx‐VCC
Number of subjects: 181
Study 17700289 — intervention group
Group type: EXPERIMENTAL
Intervention: GDx‐VCC combined with M‐FDT
Number of subjects: 181
Study 17700289 — intervention group
Group type: EXPERIMENTAL
Intervention: NFI combined with GDx‐VCC nerve fiber bundle defect criterion
Number of subjects: 181
Study 17700289 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination of M‐FDT with the latter pair of criteria
Number of subjects: 181
Study 16432644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational intervention (three mailings)
Number of subjects: 1185
Study 14571485 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent intervention
Number of subjects: 955
Study 10730980 — intervention group
Group type: COMPARATOR
Intervention: PGF2alpha treatment
Number of subjects: 30
Study 10730980 — intervention group
Group type: COMPARATOR
Intervention: Progesterone treatment (100 mg daily from Days 10 to 30)
Number of subjects: 30
Study 10730980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 8803525 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1452 (50 mg) with food
Number of subjects: 8
Study 8803525 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1452 (50 mg) without food
Number of subjects: 8
Study 8803525 — intervention group
Group type: COMPARATOR
Intervention: S-1452 (50 mg) with food and without food
Number of subjects: 8
Study 1630666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg daily
Number of subjects: 0
Study 1630666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 0
Study 6142348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of one extra-large egg for three weeks
Number of subjects: 17
Study 6142348 — intervention group
Group type: COMPARATOR
Intervention: Ingestion of isocaloric eggless foods for three weeks
Number of subjects: 17
Study 31863465 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world data collection from electronic health records, mobile applications, wearables, and social media
Number of subjects: 0
Study 30936313 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief science-based online diversity training
Number of subjects: 3016
Study 30936313 — intervention group
Group type: COMPARATOR
Intervention: Active placebo control
Number of subjects: 3016
Study 28489511 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg twice per day)
Number of subjects: 312
Study 28489511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 25380077 — intervention group
Group type: COMPARATOR
Intervention: Shared care
Number of subjects: 287
Study 25380077 — intervention group
Group type: COMPARATOR
Intervention: Nurse consultations
Number of subjects: 287
Study 25380077 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatologist consultations
Number of subjects: 287
Study 23187951 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of β‐glucans daily for 8 weeks
Number of subjects: 59
Study 21489769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.625 mg/mL with epinephrine 5 μg/mL at 10 mL/hr
Number of subjects: 60
Study 21489769 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.625 mg/mL at 10 mL/hr
Number of subjects: 60
Study 19069713 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural injection of 1 ml of betamethasone after surgical decompression
Number of subjects: 40
Study 19069713 — intervention group
Group type: COMPARATOR
Intervention: Surgical decompression of the median nerve by open release of the carpal tunnel
Number of subjects: 40
Study 17023253 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric needle electrode
Number of subjects: 80
Study 17023253 — intervention group
Group type: COMPARATOR
Intervention: Monopolar needle electrode
Number of subjects: 80
Study 17023253 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric needle electrode (APB muscle)
Number of subjects: 80
Study 17023253 — intervention group
Group type: COMPARATOR
Intervention: Biceps muscle (Monopolar needle)
Number of subjects: 80
Study 17023253 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle preference (Concentric)
Number of subjects: 80
Study 17023253 — intervention group
Group type: COMPARATOR
Intervention: Needle preference (Monopolar)
Number of subjects: 80
Study 17023253 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle preference
Number of subjects: 80
Study 15332470 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice at home (HAH)
Number of subjects: 96
Study 15332470 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of inadequate terminal support
Number of subjects: 96
Study 15332470 — intervention group
Group type: EXPERIMENTAL
Intervention: High symptom severity
Number of subjects: 96
Study 15332470 — intervention group
Group type: EXPERIMENTAL
Intervention: Home deaths
Number of subjects: 96
Study 15332470 — intervention group
Group type: COMPARATOR
Intervention: Inpatient deaths
Number of subjects: 96
Study 11078298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologist A's interpretation of angiographic reports
Number of subjects: 209
Study 11078298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologist B's interpretation of angiographic reports
Number of subjects: 209
Study 11078298 — intervention group
Group type: EXPERIMENTAL
Intervention: Unanimous agreement on the number of narrowed arteries
Number of subjects: 209
Study 11078298 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual management vs. Cardiologist A's recommendations
Number of subjects: 209
Study 11078298 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual management vs. Cardiologist B's recommendations
Number of subjects: 209
Study 11078298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologist B's agreement in the subset of 92 patients
Number of subjects: 209
Study 9403286 — intervention group
Group type: EXPERIMENTAL
Intervention: Light breakfast
Number of subjects: 0
Study 9403286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked breakfast
Number of subjects: 0
Study 9403286 — intervention group
Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 0
Study 1402291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 27
Study 1402291 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol (Control)
Number of subjects: 27
Study 3913752 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-Hydroxytryptophan (L-5-HTP)
Number of subjects: 31
Study 3913752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 29533686 — intervention group
Group type: EXPERIMENTAL
Intervention: MIES-1 (single serving)
Number of subjects: 24
Study 29533686 — intervention group
Group type: EXPERIMENTAL
Intervention: MIES-2 (two servings)
Number of subjects: 24
Study 29533686 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study 29533686 — intervention group
Group type: EXPERIMENTAL
Intervention: MIES (all doses)
Number of subjects: 24
Study 30427213 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPATIC program
Number of subjects: 31
Study 30427213 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive‐behavioral therapy (CBT)
Number of subjects: 31
Study 26970721 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM-guided anti-tuberculosis treatment initiation
Number of subjects: 2528
Study 26970721 — intervention group
Group type: COMPARATOR
Intervention: Routine diagnostic tests alone (no LAM)
Number of subjects: 2528
Study 24524676 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS stimulants (methylphenidate or dexamphetamine)
Number of subjects: 10
Study 24524676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21681140 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy (surgery)
Number of subjects: 1192
Study 21681140 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative care (control)
Number of subjects: 1192
Study 20033810 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT with docetaxel, cisplatin, and 5-fluorouracil (TPF)
Number of subjects: 100
Study 20033810 — intervention group
Group type: COMPARATOR
Intervention: CCRT with cisplatin, 5-fluorouracil, methotrexate, and leucovorin (PFML)
Number of subjects: 100
Study 17426304 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Problem-Solving Scale (DPSS)
Number of subjects: 64
Study 17426304 — intervention group
Group type: EXPERIMENTAL
Intervention: DPSS subscales (Impulsive Style, Negative Transfer of Past Experience/Learning, Negative Motivation)
Number of subjects: 64
Study 16385425 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated Progressive Relaxation Training (APRT)
Number of subjects: 55
Study 16385425 — intervention group
Group type: COMPARATOR
Intervention: Control (quiet sitting)
Number of subjects: 55
Study 11871363 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 535